Private equity firm Advent International is in advanced talks to acquire inVentivGroup Holdings in a deal that could value the U.S. pharmaceutical research firm at close to $4 billion, including debt, people familiar with the matter said on Sunday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
